Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.34 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16618858 | 0.99 | RORC (0.38) | RORCALDH1A1L3MBTL1HTR6MEN1 | |
| SCHEMBL16626509 | 0.93 | RORC (0.38) | RORCALDH1A1L3MBTL1HTR6MEN1 | |
| Hydrochloric Acid SCHEMBL16618848 | 0.93 | RORC (0.38) | RORCALDH1A1L3MBTL1HTR6MEN1 | |
| SCHEMBL16626497 | 0.93 | RORC (0.38) | RORCALDH1A1L3MBTL1HTR6MEN1 | |
| Hydrochloric Acid SCHEMBL16619483 | 0.92 | RORC (0.37) | RORCALDH1A1L3MBTL1HTR6MEN1 | |
| SCHEMBL16626748 | 0.91 | RORC (0.38) | RORCALDH1A1L3MBTL1HTR6ALOX15 | |
| SCHEMBL17971552 | 0.90 | HTR6 (0.41) | HTR6 | |
| SCHEMBL16626738 | 0.90 | HTR6 (0.44) | HTR6CYP3A4 | |
| Hydrochloric Acid SCHEMBL16618931 | 0.90 | RORC (0.38) | RORCALDH1A1L3MBTL1HTR6ALOX15 | |
| Hydrochloric Acid SCHEMBL16619279 | 0.89 | HTR6 (0.41) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | claimed |
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| WO-2015050412-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | GIPR, PGC, SI | RORC 1067/4885ALDH1A1 2153/4885L3MBTL1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.